The annual conference of the Biotechnology Innovation Organization (BIO) is always an anticipated gathering where pharma and ...

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...

The Inflation Reduction Act (IRA), signed into law in August 2022, marked a historic shift in US healthcare policy by ...

Liver damage is a well-recognised complication of gene therapies based on adeno-associated virus (AAV) vectors, and other ...

Streeting has also promised to reduce the time it takes to get clinical trials approved by cutting red tape, pointing out ...

Jeremy Skillington, CEO of LSE-listed Poolbeg Pharma, which has programmes targeting areas of high unmet medical need, ...

New research reveals some significant imbalances between healthcare professionals' (HCP) demand and industry's provision of medical information, based on content types, channels and format.

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological cancer multiple myeloma, in the latest stage of the medicine's renaissance.

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

FDA Commissioner Dr Marty Makary. The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory reviews, announcing its launch nearly a ...